About INLYTA

INLYTA is a prescription medication used to treat certain types of cancer, including renal cell carcinoma (RCC) and non-small cell lung cancer (NSCLC). It contains the active ingredient axitinib, a tyrosine kinase inhibitor that works by blocking the growth of cancer cells.

Key Benefits & Uses

Treatment of advanced renal cell carcinoma (RCC) after failure of one prior therapy
Treatment of advanced non-small cell lung cancer (NSCLC) with a PD-L1 tumor proportion score (TPS) of 1% or higher as determined by an FDA-approved test
First-line treatment of advanced renal cell carcinoma (RCC)

Active Ingredient & Action

Axitinib, the active ingredient in INLYTA, works by selectively inhibiting the activity of multiple receptor tyrosine kinases (RTKs), including vascular endothelial growth factor receptors (VEGFRs), platelet-derived growth factor receptors (PDGFRs), and other kinases involved in tumor growth and angiogenesis.

Important Notes

INLYTA is available in 1 mg and 5 mg tablets. It is recommended to take INLYTA orally once daily with or without food. Patients should be monitored for hypertension, proteinuria, and liver function abnormalities. INLYTA may cause serious side effects, including hypertension, bleeding, and liver damage. Patients should be advised to report any unusual symptoms or side effects to their healthcare provider.